ABSTRACT
The clinical significance of molecular detection of respiratory viruses in bronchoalveolar lavage (BAL) samples is poorly defined. We performed an observational retrospective study including all patients who underwent a BAL procedure in our institution, regardless of the reason for bronchoscopy, from January 2015 to December 2018. Respiratory viruses were detected by real-time polymerase chain reaction with a commercial multiplex panel, and a cell culture was performed to detect cytomegalovirus and herpes simplex virus. Positive results were correlated with clinical symptoms and patients' characteristics. Of 540 BAL samples analyzed, 113 (20.9%) were positive for any respiratory virus. Viral detection was significantly associated with respiratory symptoms (83.2% vs. 68.9%, p = .004) and radiological infiltrates (67.3% vs. 52.2%, p = .006). The most frequent viruses detected were rhinovirus (42/113, 37.2%), influenza virus (20/113, 17.7%), and parainfluenza virus (PIV) (16/113, 14.2%). Respiratory pathogens codetections were found in 51/113 (45.1%) BAL samples, including more than one virus (16/51, 31.4%), fungi (8/51, 15.7%), and bacteria (9/51, 17.6%). Viral detection was significantly higher in immunocompromised patients (26.5% vs. 16.9%; p = .022). PIV and human metapneumovirus were mostly observed in lung (50.0%, 8/16) and hemopoietic transplant recipients (25%, 2/8), respectively, with clinical repercussions. Our data underline that molecular diagnosis allows identification of viral agents as the etiology of respiratory infections; however, the high frequency of codetections hinders identification of the agent responsible for the current respiratory symptomatology. Immunocompromised patients are the target population in whom to investigate the presence of respiratory viruses in their BAL samples.
Subject(s)
Bronchoalveolar Lavage Fluid/virology , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/virology , Viruses/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Genome, Viral , Humans , Immunocompromised Host , Male , Middle Aged , Retrospective Studies , Spain/epidemiology , Viruses/classification , Viruses/isolation & purification , Young AdultABSTRACT
OBJECTIVES: This study focused on the role that BK polyomavirus (BKPyV) genotypes can play in the development of BKPyV-associated complications in renal transplant recipients. METHODS: A retrospective observational study (January 2015 to April 2018) was conducted by analyzing BKPyV genotypes in 180 blood samples with detectable BKPyV viral load (VL) > 1000 copies/mL, from 63 renal transplant recipients. VL and BKPyV genotypes detections were based on real-time PCR (rt-PCR)-specific assays. RESULTS: Forty-four patients (44/63 [69.8%]) were men, and the median age was 55.0 (interquartile range 49.0-66.0 years). Eleven patients had clinical manifestations (11/63 [17.5%]). The most frequently detected genotypes were I (14/63 [22.2%]) and II (13/63 [20.6%]). Half of the patients (33/63 [52.4%]) had a mixed genotype, most with genotypes I and II (25/33 [75.8%]). Patients with infection by mixed genotypes showed VLs that were detected earlier (in the first year after transplantation) than those with a single genotype (25/33 [75.8%] vs 13/30 [43.3%], P = .009) and demonstrated greater risk of developing clinical manifestations associated with BKPyV (odds ratio 12.609, 95% confidence interval 1.503-105.807). Moreover, patients with first BKPyV VL > 10 000 copies/mL more frequently presented mixed genotypes (12/16 [75.0%] vs 21/47 [44.7%], P = .036). CONCLUSIONS: The probability of developing clinical manifestations is higher in infections by mixed genotypes. Therefore, the detection of BKPyV genotypes by rt-PCR can provide relevant information to stratify patients' risk of BKPyV-associated complications and guide the clinical management of BKPyV infection in kidney transplant recipients.
Subject(s)
BK Virus , Kidney Diseases , Kidney Transplantation , Polyomavirus Infections , Tumor Virus Infections , Aged , BK Virus/genetics , Genotype , Humans , Kidney Transplantation/adverse effects , Male , Middle Aged , Polyomavirus Infections/diagnosis , Polyomavirus Infections/epidemiology , Retrospective Studies , Transplant Recipients , Tumor Virus Infections/epidemiologyABSTRACT
BACKGROUND: The increasing risk of obesity and diabetes among other metabolic disorders are the consequence of shifts in dietary patterns with high caloric-content food intake. We previously reported that megalin regulates energy homeostasis using blood-brain barrier (BBB) endothelial megalin-deficient (EMD) mice, since these animals developed obesity and metabolic syndrome upon normal chow diet administration. Obesity in mid-life appears to be related to greater dementia risk and represents an increasing global health issue. We demonstrated that EMD phenotype induced impaired learning ability and recognition memory, neurodegeneration, neuroinflammation, reduced neurogenesis, and mitochondrial deregulation associated with higher mitochondrial mass in cortical tissues. METHODS: EMD mice were subjected to normal chow and high-fat diet (HFD) for 14 weeks and metabolic changes were evaluated. RESULTS: Surprisingly, BBB megalin deficiency protected against HFD-induced obesity improving glucose tolerance and preventing hepatic steatosis. Compared to wild type (wt), the brain cortex in EMD mice showed increased levels of the mitochondrial biogenesis regulator, peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), and uncoupling protein 2 (UCP2), a thermogenic protein involved in the regulation of energy metabolism. This agreed with the previously found increased mitochondrial mass in the transgenic mice. Upon HFD challenge, we demonstrated these two proteins were found elevated in wt mice but reported no changes over the already increased levels in EMD animals. CONCLUSION: We propose a protective role for megalin on diet-induce obesity, suggesting this could be related to metabolic disturbances found in dementia through brain endocrine system communications.
Subject(s)
Blood-Brain Barrier/metabolism , Brain/metabolism , Diet, High-Fat/adverse effects , Endothelium, Vascular/metabolism , Low Density Lipoprotein Receptor-Related Protein-2/metabolism , Animals , Energy Metabolism/physiology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Obesity/metabolismABSTRACT
Automation of viral diagnosis has led to an increase of BK virus (BKV) viral load (VL) requests. The aim of this study was to assess the suitability of serum creatinine (SCr) for controlling the demand and to study the clinical characteristics of BKV infection. This is a retrospective study including patients with BKV VL request during April-July 2017. Clinical records and SCr were analyzed. Five hundred samples from 333 patients were included; 61.4% of samples were from males (55.5 ± 14.8 years), and all belonged to transplant recipients (86.4% renal). BKV VL was detectable in 40 samples (8.0%) from 23 patients (6.9%), who presented high SCr (100% vs. 90.9%, P = 0.038). Most of detectable VLs (62.5%) belonged to patients in their first year post-transplant. Six patients with detectable VL (26.1%) developed clinical manifestations, most of them (83.3%) had a first BKV VL greater than 10,000 copies/mL (P = 0.001). In conclusion, SCr would be useful to identify suitable specimens for BKV VL testing without missing cases.
Subject(s)
BK Virus/isolation & purification , Diagnostic Services/statistics & numerical data , Facilities and Services Utilization/statistics & numerical data , Polyomavirus Infections/diagnosis , Viral Load , Adult , Aged , Blood Chemical Analysis , Creatinine/blood , Female , Humans , Male , Middle Aged , Retrospective Studies , Transplant RecipientsABSTRACT
BACKGROUND: The multiligand receptor megalin controls the brain uptake of a number of ligands, including insulin and leptin. Despite the role of megalin in the transport of these metabolically relevant hormones, the role of megalin at the blood-brain-barrier (BBB) has not yet been explored in the context of metabolic regulation. METHODS: Here we investigate the role of brain endothelial megalin in energy metabolism and leptin signaling using an endothelial cell-specific megalin deficient (EMD) mouse model. RESULTS: We found megalin is important to protect mice from developing obesity and metabolic syndrome when mice are fed a normal chow diet. EMD mice developed neuroinflammation, by triggering several pro-inflammatory cytokines, displayed reduced neurogenesis and mitochondrial deregulation. CONCLUSIONS: These results implicate brain endothelial megalin expression in obesity-related metabolic changes through the leptin signaling pathway proposing a potential link between obesity and neurodegeneration.
Subject(s)
Encephalitis/genetics , Encephalitis/pathology , Endothelial Cells/metabolism , Low Density Lipoprotein Receptor-Related Protein-2/deficiency , Obesity/genetics , Obesity/pathology , Age Factors , Animals , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/pathology , Brain/physiopathology , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Doublecortin Domain Proteins , Eating/genetics , Glial Fibrillary Acidic Protein/metabolism , Low Density Lipoprotein Receptor-Related Protein-2/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Microtubule-Associated Proteins/metabolism , Mitochondria/pathology , Mitochondria/ultrastructure , Neuropeptides/metabolism , Phosphopyruvate Hydratase/metabolism , STAT3 Transcription Factor/metabolismABSTRACT
Several studies have implicated the enzyme acetylcholinesterase (AChE) as well as several biometals in the pathogenesis of Alzheimer's disease (AD). A multifunctional molecule, the hybrid tacrine-8-hydroxyquinoline (named IQM-622), displays cholinergic, antioxidant, copper-complexing and neuroprotective properties. Using in vitro and in vivo models, we investigated the modulating effects of IQM-622 on amyloid ß-protein (Aß)-induced pathology as well as on chemically induced neurodegeneration by domoic acid. In the first experimental model, we observed a significant decrease in brain Aß deposits in IQM-622-treated APP/Ps1 mice for four weeks. Moreover, IQM-622 promoted the degradation of intracellular Aß in astrocytes, and protected against Aß toxicity in cultured astrocytes and neurons. These findings suggest that the neuroprotective effect of IQM-622 is not only related to AChE inhibition, but also involves other mechanisms, including the modulation of Aß-degradation pathways in AD brain. In this study we also compare the neuronal loss in CA1 hippocampal field of AD patients and of mice treated with domoic acid, giving similar patterns. Thus, we used a second experimental model by killing hippocampal neurons by domoic acid damage, in which IQM-622 increased survival in the CA1 and dentate gyrus regions of the hippocampus. Our observations suggest that administration of IQM-622 may have significant beneficial effects in neurodegenerative diseases, including AD, which course with acute or progressive neuronal death.
Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Cell Death/drug effects , Hippocampus/metabolism , Hippocampus/pathology , Hydroxyquinolines/pharmacology , Neurons/metabolism , Neurons/pathology , Neuroprotective Agents/pharmacology , Tacrine/analogs & derivatives , Amyloid beta-Protein Precursor/genetics , Animals , Astrocytes/drug effects , Cells, Cultured , Humans , Immunohistochemistry , Mice , Mice, Transgenic , Presenilin-1/genetics , Tacrine/pharmacologyABSTRACT
The original version of this article unfortunately contained some mistakes.
ABSTRACT
In Alzheimer's disease (AD) amyloid-ß (Aß) deposits may cause impairments in choroid plexus, a specialised brain structure which forms the blood-cerebrospinal fluid (CSF) barrier. We previously carried out a mass proteomic-based study in choroid plexus from AD patients and we found several differentially regulated proteins compared with healthy subjects. One of these proteins, annexin A5, was previously demonstrated implicated in blocking Aß-induced cytotoxicity in neuronal cell cultures. Here, we investigated the effects of annexin A5 on Aß toxicity in choroid plexus. We used choroid plexus tissue samples and CSF from mild cognitive impairment (MCI) and AD patients to analyse Aß accumulation, cell death and annexin A5 levels compared with control subjects. Choroid plexus cell cultures from rats were used to analyse annexin A5 effects on Aß-induced cytotoxicity. AD choroid plexus exhibited progressive reduction of annexin A5 levels along with progressive increased Aß accumulation and cell death as disease stage was higher. On the other hand, annexin A5 levels in CSF from patients were found progressively increased as the disease stage increased in severity. In choroid plexus primary cultures, Aß administration reduced endogenous annexin A5 levels in a time-course dependent manner and simultaneously increased annexin A5 levels in extracellular medium. Annexin A5 addition to choroid plexus cell cultures restored the Aß-induced impairments on autophagy flux and apoptosis in a calcium-dependent manner. We propose that annexin A5 would exert a protective role in choroid plexus and this protection is lost as Aß accumulates with the disease progression. Then, brain protection against further toxic insults would be jeopardised.
Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Annexin A5/metabolism , Blood-Brain Barrier/pathology , Choroid Plexus/physiology , Cognitive Dysfunction/metabolism , Neurons/pathology , Aged , Aged, 80 and over , Alzheimer Disease/genetics , Animals , Apoptosis , Autophagy , Calcium/metabolism , Cells, Cultured , Cognitive Dysfunction/genetics , Female , Humans , Male , Middle Aged , Proteomics , Rats , Rats, WistarABSTRACT
Respiratory viral infections are the most frequent clinical syndrome affecting both children and adults, and early detection is fundamental to avoid infection-related risks and reduce the healthcare costs incurred by unnecessary antibiotic treatments. In this study, performance characteristics of two commercial methods, the Panther Fusion® assay (Hologic Inc., San Diego, CA, USA) were compared to Allplex™ respiratory panels (Seegene, Seoul, South Korea) for the detection of influenza A (Flu A), influenza B (Flu B), respiratory syncytial virus (RSV), parainfluenza virus (PIV), human metapneumovirus (hMPV), rhinovirus (RV) and adenovirus (AdV) targets. A total of 865 specimens collected prospectively and retrospectively were included, and discordant results were further examined using another commercial product, R-GENE™ respiratory kits (bioMérieux, Marcy l'Etoile, France). There was high agreement between both methods, with 98.6% concordance and a kappa (k) value of 0.9 (95% CI: 0.89-0.92). A specific analysis of both methods for each viral agent demonstrated comparable sensitivity and specificity, both ranging from 0.83 to 1 with good predictive values for the prospective part of the study. Good agreement between both methods was also found for the κ values obtained (ranging from 97.55% to 98.9%), with the lowest for hMPV (k = 0.83, 95% CI: 0.75-0.91) and RV (k = 0.73, 95% CI: 0.65-0.81). Amplification efficiency, measured according to the value of the cycle threshold (Ct) obtained in each of the amplifications in both tests, was significantly better with Panther Fusion for Flu A, Flu B, hMPV and RV. Regarding discordant results, R-GENE showed higher agreement with Panther Fusion-positive specimens (negative for Allplex; n = 28/71, 34.9%) than with Allplex-positive samples (negative for Panther Fusion; n = 7/49, 14.3%). In summary, Panther Fusion proved to be a more efficient fully-automated methodology, requiring shorter hands-on and turnaround times than Allplex.
Subject(s)
Reagent Kits, Diagnostic , Respiratory Tract Infections/virology , Virus Diseases/diagnosis , Adenoviridae/isolation & purification , Female , Humans , Influenza A virus/isolation & purification , Betainfluenzavirus/isolation & purification , Metapneumovirus/isolation & purification , Prospective Studies , Respiratory Syncytial Viruses/isolation & purification , Respirovirus/isolation & purification , Retrospective Studies , Rhinovirus/isolation & purification , Sensitivity and SpecificityABSTRACT
BACKGROUND: The phosphodiesterase (PDE) 7 inhibitor S14 is a cell-permeable small heterocyclic molecule that is able to cross the blood-brain barrier. We previously found that intraperitoneal treatment with S14 exerted neuroprotection in an Alzheimer's disease (AD) model (in APP/PS1 mice). The objective of this study was to investigate the neurogenic and cellular effects of oral administration of S14 on amyloid ß (Aß) overload. METHODS: We orally administered the PDE7 inhibitor S14 (15 mg/kg/day) or vehicle in 6-month-old APP/PS1 mice. After 5 weeks of S14 treatment, we evaluated cognitive functions and brain tissues. We also assessed the effects of S14 on the Aß-treated human neuroblastome SH-SY5Y cell line. RESULTS: Targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element binding protein (CREB) pathway, S14 rescued cognitive decline by improving hippocampal neurogenesis in APP/PS1 transgenic mice. Additionally, S14 treatment reverted the Aß-induced reduction in mitochondrial mass in APP/PS1 mice and in the human neuroblastoma SH-SY5Y cells co-exposed to Aß. The restoration of the mitochondrial mass was found to be a dual effect of S14: a rescue of the mitochondrial biogenesis formerly slowed down by Aß overload, and a reduction in the Aß-increased mitochondrial clearance mechanism of mitophagy. CONCLUSIONS: Here, we show new therapeutic effects of the PDE7 inhibitor, confirming S14 as a potential therapeutic drug for AD.
Subject(s)
Alzheimer Disease/complications , Alzheimer Disease/enzymology , Hippocampus/drug effects , Mitochondrial Dynamics/drug effects , Neurogenesis/drug effects , Phosphodiesterase Inhibitors/pharmacology , Quinazolines/pharmacology , Alzheimer Disease/drug therapy , Alzheimer Disease/genetics , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Animals , Cell Line, Tumor , Cyclic Nucleotide Phosphodiesterases, Type 7/metabolism , Disease Models, Animal , Embryo, Mammalian , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , Hippocampus/pathology , Humans , Learning Disabilities/drug therapy , Learning Disabilities/etiology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Mitochondrial Dynamics/genetics , Neurogenesis/genetics , Phosphodiesterase Inhibitors/therapeutic use , Quinazolines/therapeutic use , Rats , Rats, Wistar , Signal Transduction/drug effects , Signal Transduction/geneticsABSTRACT
Neurogenesis in the adult hippocampus is a unique process in neurobiology that requires functional integration of newly generated neurons, which may disrupt existing hippocampal network connections and consequently loss of established memories. As neurodegenerative diseases characterized by abnormal neurogenesis and memory dysfunctions are increasing, the identification of new anti-aging drugs is required. In adult mice, we found that melatonin, a well-established neurogenic hormone, and the melatonin analog 2-(2-(5-methoxy-1 H-indol-3-yl)ethyl)-5-methyl-1,3,4-oxadiazole (IQM316) were able to induce hippocampal neurogenesis, measured by neuronal nuclei (NeuN) and 5-bromo-2'-deoxyuridine (BrdU) labeling. More importantly, only IQM316 administration was able to induce hippocampal neurogenesis while preserving previously acquired memories, assessed with object recognition tests. In vitro studies with embryonic neural stem cells replicated the finding that both melatonin and IQM316 induce direct differentiation of neural precursors without altering their proliferative activity. Furthermore, IQM316 induces differentiation through a mechanism that is not dependent of melatonergic receptors (MTRs), since the MTR antagonist luzindole could not block the IQM316-induced effects. We also found that IQM316 and melatonin modulate mitochondrial DNA copy number and oxidative phosphorylation proteins, while maintaining mitochondrial function as measured by respiratory assays and enzymatic activity. These results uncover a novel pharmacological agent that may be capable of inducing adult hippocampal neurogenesis at a healthy and sustainable rate that preserves recognition memories.
Subject(s)
Hippocampus/drug effects , Melatonin/pharmacology , Animals , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Male , Memory/drug effects , Memory, Long-Term/drug effects , Mice , Mice, Inbred C57BL , Neural Stem Cells/drug effects , Neurogenesis/drug effects , Neurons/drug effects , Tryptamines/pharmacologyABSTRACT
Platelets are considered a good model system to study a number of elements associated with neuronal pathways as they share biochemical similarities. Platelets represent the major source of amyloid-ß (Aß) in blood contributing to the Aß accumulation in the brain parenchyma and vasculature. Peripheral blood platelet alterations including cytoskeletal abnormalities, abnormal cytoplasmic calcium fluxes or increased oxidative stress levels have been related to Alzheimer's disease (AD) pathology. Therefore, platelets can be considered a peripheral model to study metabolic mechanisms occurring in AD. To investigate peripheral molecular alterations, we examined platelet protein expression in a cohort of 164 subjects, including mild cognitive impairment (MCI), and AD patients, and healthy aged-matched controls. A two-dimensional difference gel electrophoresis (2D-DIGE) discovery phase revealed significant differences between patients and controls in five proteins: talin, vinculin, moesin, complement C3b and Rho GDP, which are known to be involved in cytoskeletal regulation including focal adhesions, inflammation and immune functions. Western blot analysis verified that talin was found to be increased in mild and moderate AD groups versus control, while the other three were found to be decreased. We also analysed amyloid precursor protein (APP), amyloid-ß 1-40 (Aß40) and 1-42 (Aß42) levels in platelets from the same groups of subjects. Upregulation of platelet APP and Aß peptides was found in AD patients compared to controls. These findings complement and expand previous reports concerning the morphological and functional alterations in AD platelets, and provide more insights into possible mechanisms that participate in the multifactorial and systemic damage in AD.
Subject(s)
Alzheimer Disease/blood , Alzheimer Disease/immunology , Blood Platelets/metabolism , Cytoskeleton/metabolism , Proteomics/methods , Aged , Amyloid beta-Peptides/blood , Case-Control Studies , Cognitive Dysfunction/blood , Female , Humans , Male , Reproducibility of ResultsABSTRACT
Parkinson's disease is a common neurodegenerative disorder of unknown pathogenesis characterized by the loss of nigrostriatal dopaminergic neurons. Oxidative stress, microglial activation and inflammatory responses seem to contribute to the pathogenesis. Recent data showed that growth factors mediate neuroprotection in rodent models of Parkinson's disease, modulating pro-inflammatory processes. Based on our recent studies showing that plasma rich in growth factors (PRGF-Endoret) mediates neuroprotection as inflammatory moderator in Alzheimer's disease, in the present study we examined the effects of plasma rich in growth factors (PRGF-Endoret) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mouse as a translational therapeutic approach for Parkinson's disease. We found substantial neuroprotection by PRGF-Endoret in our model of Parkinson's disease, which resulted in diminished inflammatory responses and improved motor performance. Additionally, these effects were associated with robust reduction in nuclear transcription factor-κB (NF-κB) activation, and nitric oxide (NO), cyclooxygenase-2 (COX-2), and tumor necrosis factor-alpha (TNF-α) expression in the substantia nigra. We propose that PRGF-Endoret can prevent dopaminergic degeneration via an NF-κB-dependent signaling process. As the clinical safety profile of PRGF-Endoret is already established, these data suggest that PRGF-Endoret provides a novel neuroprotective strategy for Parkinson's disease.
Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Dopaminergic Neurons/drug effects , Inflammation/drug therapy , Intercellular Signaling Peptides and Proteins/therapeutic use , NF-kappa B/immunology , Parkinson Disease, Secondary/drug therapy , Administration, Intranasal , Animals , Cell Line, Tumor , Cell Survival/drug effects , Disease Models, Animal , Dopaminergic Neurons/immunology , Dopaminergic Neurons/pathology , Humans , Inflammation/immunology , Inflammation/pathology , Intercellular Signaling Peptides and Proteins/administration & dosage , Male , Mice , Mice, Inbred C57BL , Parkinson Disease, Secondary/immunology , Parkinson Disease, Secondary/pathology , Substantia Nigra/drug effects , Substantia Nigra/immunology , Substantia Nigra/pathologyABSTRACT
Recent studies indicate that the choroid plexus has important physiologic and pathologic roles in Alzheimer disease (AD). To obtain additional insight on choroid plexus function, we performed a proteomic analysis of choroid plexus samples from patients with AD stages I to II (n = 16), III to IV (n = 16), and V to VI (n = 11) and 7 age-matched control subjects. We used 2-dimensional differential gel electrophoresis coupled with mass spectrometry to generate a complete picture of changes in choroid plexus protein expression occurring in AD patients. We identified 6 proteins: 14-3-3 ß/α, 14-3-3 ε, moesin, proteasome activator complex subunit 1, annexin V, and aldehyde dehydrogenase, which were significantly regulated in AD patient samples (p < 0.05, >1.5-fold variation in expression vs control samples). These proteins are implicated in major physiologic functions including mitochondrial dysfunction and apoptosis regulation. These findings contribute additional significance to the emerging importance of molecular and functional changes of choroid plexus function in the pathophysiology of AD.
Subject(s)
Adaptor Proteins, Signal Transducing/biosynthesis , Alzheimer Disease/metabolism , Choroid Plexus/metabolism , Gene Expression Regulation , 14-3-3 Proteins/biosynthesis , Aged , Aged, 80 and over , Aldehyde Dehydrogenase/biosynthesis , Alzheimer Disease/pathology , Annexin A5/biosynthesis , Choroid Plexus/pathology , Early Diagnosis , Humans , Male , Microfilament Proteins/biosynthesisABSTRACT
Megalin or low-density lipoprotein receptor-related protein-2 is a member of the low-density lipoprotein receptor family, which has been linked to Alzheimer's disease (AD) by clearing brain amyloid ß-peptide (Aß) across the blood-cerebrospinal fluid barrier at the choroid plexus. Here, we found a soluble form of megalin secreted from choroid plexus epithelial cells. Soluble megalin levels were also localized in the human cerebrospinal fluid (CSF), being reduced in AD patients. We have also shown that soluble megalin binding to Aß is decreased in the CSF of AD patients, suggesting that decreased sequestration of Aß in the CSF could be associated with defective clearance of Aß and an increase of brain Aß levels. Thus, therapies, which increase megalin expression, at the choroid plexus and/or enhance circulating soluble megalin hold potential to control brain Aß-related pathologies in AD.
ABSTRACT
Megalin has been suggested to be involved in Alzheimer's disease (AD), mediating blood-brain barrier (BBB) transport of multiple ligands, including amyloid-ß peptide (Aß), but also neuroprotective factors. Because no transgenic model is currently available to study this concept, we have obtained transgenic mice blocking megalin expression at the BBB. These endothelial megalin deficient (EMD) mice developed increased anxiety behavior and impaired learning ability and recognition memory, similar to symptoms described in AD. Degenerating neurons were also observed in the cerebral cortex of EMD mice. In view of our findings we suggest that, in mice, megalin deficiency at the BBB leads to neurodegeneration.
Subject(s)
Alzheimer Disease/metabolism , Cognition Disorders/metabolism , Endothelial Cells/metabolism , Low Density Lipoprotein Receptor-Related Protein-2/deficiency , Alzheimer Disease/genetics , Alzheimer Disease/pathology , Animals , Cells, Cultured , Cognition Disorders/genetics , Cognition Disorders/pathology , Endothelial Cells/pathology , Humans , Low Density Lipoprotein Receptor-Related Protein-2/genetics , Male , Mice , Mice, Knockout , Mice, TransgenicABSTRACT
Impaired growth factor function is thought to drive many of the alterations observed in Alzheimer's disease (AD) patients. Endogenous regenerative technology, PRGF (plasma rich in growth factor)-Endoret, is designed for the delivery of a complex pool of patient's own active morphogens that may stimulate tissue regeneration. We obtained and characterized PRGF-Endoret preparations from human blood. We used, as experimental approach in vivo, APP/PS1 mice, characterized by age-dependent brain amyloid-ß (Aß) accumulation. Intranasal administration of PRGF-Endoret to APP/PS1 mice resulted in an important decrease in brain Aß deposition and tau phosphorylation. PRGF-Endoret-treated APP/PS1 mice also showed decreased astrocyte reactivity, and prevented protein synaptic loss. In vitro approaches demonstrated that PRGF-Endoret treatment modulated astrocyte activation, reducing inflammatory responses, and promoted Aß degradation. Furthermore, PRGF-Endoret stimulated global improvements in anxiety, learning, and memory behaviors. Our findings show that PRGF-Endoret exerts multifunctional and complementary effects that result in the reversal of the broad range of cognitive deficits in AD, suggesting that PRGF-Endoret may hold promise as an innovative therapy in AD.
Subject(s)
Alzheimer Disease/drug therapy , Cognition/drug effects , Disease Models, Animal , Intercellular Signaling Peptides and Proteins/administration & dosage , Mice, Transgenic , Administration, Intranasal , Alzheimer Disease/psychology , Amyloid beta-Peptides/metabolism , Animals , Anxiety , Astrocytes/drug effects , Brain/metabolism , Cells, Cultured , Humans , Intercellular Signaling Peptides and Proteins/pharmacology , Intercellular Signaling Peptides and Proteins/physiology , Learning/drug effects , Male , Memory/drug effects , Mice , Phosphorylation/drug effects , Plasma , tau Proteins/metabolismABSTRACT
Neurodegeneration together with a reduction in neurogenesis are cardinal features of Alzheimer's disease (AD) induced by a combination of toxic amyloid-ß peptide (Aß) and a loss of trophic factor support. Amelioration of these was assessed with diverse neurotrophins in experimental therapeutic approaches. The aim of this study was to investigate whether intranasal delivery of plasma rich in growth factors (PRGF-Endoret), an autologous pool of morphogens and proteins, could enhance hippocampal neurogenesis and reduce neurodegeneration in an amyloid precursor protein/presenilin-1 (APP/PS1) mouse model. Neurotrophic and neuroprotective actions were firstly evident in primary neuronal cultures, where cell proliferation and survival were augmented by Endoret treatment. Translation of these effects in vivo was assessed in wild type and APP/PS1 mice, where neurogenesis was evaluated using 5-bromodeoxyuridine (BdrU), doublecortin (DCX), and NeuN immunostaining 5 weeks after Endoret administration. The number of BrdU, DCX, and NeuN positive cell was increased after chronic treatment. The number of degenerating neurons, detected with fluoro Jade-B staining was reduced in Endoret-treated APP/PS1 mice at 5 week after intranasal administration. In conclusion, Endoret was able to activate neuronal progenitor cells, enhancing hippocampal neurogenesis, and to reduce Aß-induced neurodegeneration in a mouse model of AD.
Subject(s)
Alzheimer Disease/metabolism , Neurogenesis/physiology , Plasma , Adult , Aged , Aged, 80 and over , Alzheimer Disease/drug therapy , Amyloid beta-Protein Precursor/metabolism , Animals , Blotting, Western , Cells, Cultured , Disease Models, Animal , Doublecortin Protein , Female , Hippocampus/metabolism , Humans , Immunohistochemistry , Male , Mice , Middle Aged , Neurogenesis/genetics , Presenilin-1/metabolism , RatsABSTRACT
Elevated levels of amyloid beta (Aß) peptide, hyperphosphorylation of tau protein, and inflammation are pathological hallmarks in Alzheimer's disease (AD). Phosphodiesterase 7 (PDE7) regulates the inflammatory response through the cyclic adenosine monophosphate signaling cascade, and thus plays a central role in AD. The aim of this study was to evaluate the efficacy of an inhibitor of PDE7, named S14, in a mouse model of AD. We report that APP/Ps1 mice treated daily for 4 weeks with S14 show: (1) significant attenuation in behavioral impairment; (2) decreased brain Aß deposition; (3) enhanced astrocyte-mediated Aß degradation; and (4) decreased tau phosphorylation. These effects are mediated via the cyclic adenosine monophosphate/cyclic adenosine monophosphate response element-binding protein signaling pathway, and inactivation of glycogen synthase kinase (GSK)3. Our data support the use of PDE7 inhibitors, and specifically S14, as effective therapeutic agents for the prevention and treatment of AD.